Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ARNA
  • CUSIP: 04004710
  • Web: www.arenapharm.com
Capitalization:
  • Market Cap: $415.84 million
  • Outstanding Shares: 317,435,000
Average Prices:
  • 50 Day Moving Avg: $1.31
  • 200 Day Moving Avg: $1.44
  • 52 Week Range: $1.13 - $2.16
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.74
  • P/E Growth: 0.20
Sales & Book Value:
  • Annual Revenue: $120.75 million
  • Price / Sales: 3.44
  • Book Value: $0.08 per share
  • Price / Book: 16.38
Profitability:
  • EBIDTA: $18.42 million
  • Net Margins: -197.50%
  • Return on Equity: -336.85%
  • Return on Assets: -39.53%
Debt:
  • Debt-to-Equity Ratio: 15.40%
  • Current Ratio: 2.23%
  • Quick Ratio: 2.06%
Misc:
  • Average Volume: 2.48 million shs.
  • Beta: -0.64
  • Short Ratio: 4.76
 

Frequently Asked Questions for Arena Pharmaceuticals (NASDAQ:ARNA)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.01. The company earned $6.60 million during the quarter, compared to the consensus estimate of $4.84 million. Arena Pharmaceuticals had a negative net margin of 197.50% and a negative return on equity of 336.85%. The company's revenue for the quarter was down 33.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.09) earnings per share. View Arena Pharmaceuticals' Earnings History.

Where is Arena Pharmaceuticals' stock going? Where will Arena Pharmaceuticals' stock price be in 2017?

5 brokers have issued 1 year target prices for Arena Pharmaceuticals' stock. Their predictions range from $5.00 to $6.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $5.50 in the next year. View Analyst Ratings for Arena Pharmaceuticals.

What are analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Arena received a boost with the launch of Belviq XR, a once-daily, extended-release formulation of its only marketed drug, Belviq, in October. However, sales of Belviq have been lackluster so far and are yet to pick up significantly. We are encouraged by the company’s decision to shift its priorities to its proprietary clinical-stage pipeline. Notably, Arena’s pipeline consists of early-to-mid stage candidates which are still several years from commercialization. Moreover, competition remains intense in the obesity market which has both branded and generic players.  Arena’s share price has outperformed the industry in last three months. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (2/28/2017)
  • 2. FBR & Co analysts commented, "We are initiating coverage of Arena Pharmaceuticals, Inc. (ARNA) with an Outperform rating and a 12-month price target of $6 per share. Historically, ARNA focused on obesity with its one approved drug, Belviq (lorcaserin). However, given the company’s expertise in discovery and drug development targeting G protein- coupled receptors (GPCRs), it is now primarily focused on advancing the pipeline with (1) etrasimod (APD334), a S1P receptor modulator for the potential treatment of ulcerative colitis (UC); (2) ralinepag, a prostacyclin receptor (PGI2) agonist for the potential treatment of pulmonary arterial hypertension (PAH); and (3) APD371, a cannabinoid receptor 2 (CB2) agonist in development for GI pain associated with Crohn’s disease." (9/15/2016)

Are investors shorting Arena Pharmaceuticals?

Arena Pharmaceuticals saw a decline in short interest in April. As of April 28th, there was short interest totalling 7,608,463 shares, a decline of 9.8% from the April 13th total of 8,431,187 shares. Based on an average trading volume of 5,250,724 shares, the days-to-cover ratio is currently 1.4 days.

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:

  • Amit D. Munshi, President, Chief Executive Officer, Director
  • Kevin R. Lind, Chief Financial Officer, Principal Financial Officer, Executive Vice President, Principal Accounting Officer
  • Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary
  • Vincent E. Aurentz, Executive Vice President and Chief Business Officer
  • Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer
  • Maurice J. Mezzino, Senior Vice President - Corporate Development
  • Tina Susan Nova Ph.D., Lead Independent Director
  • Donald D. Belcher, Director
  • Jayson Dallas M.D., Director
  • Oliver S. Fetzer Ph.D., Director

Who owns Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (0.00%), Vanguard Group Inc. (0.00%), Renaissance Technologies LLC (0.00%), Camber Capital Management LLC (1.74%), Geode Capital Management LLC (0.00%) and Bank of New York Mellon Corp (0.48%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi and Christine Anna White. View Institutional Ownership Trends for Arena Pharmaceuticals.

Who sold Arena Pharmaceuticals stock? Who is selling Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Alliancebernstein L.P., ProShare Advisors LLC, California Public Employees Retirement System and United Services Automobile Association. View Insider Buying and Selling for Arena Pharmaceuticals.

Who bought Arena Pharmaceuticals stock? Who is buying Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., Wellington Management Group LLP, AXA, Oxford Asset Management, TFS Capital LLC, Schwab Charles Investment Management Inc. and Cornerstone Capital Management Holdings LLC.. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy Arena Pharmaceuticals stock?

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $1.31.


MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $5.50 (319.85% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Leerink SwannInitiated CoverageOutperform -> Outperform$5.00HighView Rating Details
3/16/2017FBR & CoReiterated RatingOutperform$6.00MediumView Rating Details
1/7/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
8/8/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
5/10/2016Wells Fargo & CoReiterated RatingHoldN/AView Rating Details
3/2/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
3/1/2016Royal Bank of CanadaReiterated RatingSector Perform$2.00 -> $1.50N/AView Rating Details
10/28/2015WallachBeth CapitalLower Price TargetBuy$6.00 -> $4.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Earnings History by Quarter for Arena Pharmaceuticals (NASDAQ ARNA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.08)($0.09)$4.84 million$6.60 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.08)$0.16$14.12 million$85.40 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.05)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($0.10)($0.11)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($0.10)($0.09)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($0.13)($0.13)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($0.13)($0.11)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($0.14)($0.11)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($0.14)($0.10)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($0.12)($0.15)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($0.13)($0.05)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($0.11)($0.12)$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.10)($0.12)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.02($0.11)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($0.12)($0.08)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.15$0.18$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$0.11$0.09$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.03)($0.10)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($0.11)($0.07)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.08)($0.12)ViewN/AView Earnings Details
11/9/2011($0.14)($0.16)ViewN/AView Earnings Details
8/9/2011($0.15)($0.16)ViewN/AView Earnings Details
5/10/2011($0.21)($0.35)ViewN/AView Earnings Details
3/11/2011($0.22)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)
Current Year EPS Consensus Estimate: $-0.34 EPS
Next Year EPS Consensus Estimate: $-0.35 EPS

Dividends

Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Ownership Percentage: 2.14%
Institutional Ownership Percentage: 48.99%
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Amit MunshiInsiderBuy25,000$1.19$29,750.00View SEC Filing  
4/26/2017Amit MunshiInsiderBuy50,000$1.41$70,500.00View SEC Filing  
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.72View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.00View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.00View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.00View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.25View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.00View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arena Pharmaceuticals (NASDAQ:ARNA)
Latest Headlines for Arena Pharmaceuticals (NASDAQ:ARNA)
Source:
DateHeadline
finance.yahoo.com logoArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ARNA-US : May 26, 2017
finance.yahoo.com - May 26 at 3:54 PM
americanbankingnews.com logoArena Pharmaceuticals, Inc. (ARNA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 26 at 8:50 AM
finance.yahoo.com logo5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
finance.yahoo.com - May 24 at 3:36 PM
finance.yahoo.com logo2 Marijuana Stocks That Rocketed Higher by a Double-Digit Percentage Last Week
finance.yahoo.com - May 23 at 8:53 AM
americanbankingnews.com logoAnalysts Issue Forecasts for Arena Pharmaceuticals, Inc.'s FY2020 Earnings (ARNA)
www.americanbankingnews.com - May 22 at 11:22 AM
finance.yahoo.com logoToday's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics
finance.yahoo.com - May 22 at 8:35 AM
benzinga.com logoArena Pharma Could Be Developing Several Best-In-Class Agents - Benzinga
www.benzinga.com - May 20 at 3:42 PM
finance.yahoo.com logoHere's Why Arena Pharmaceuticals Rose as Much as 18.3% Today
finance.yahoo.com - May 19 at 8:37 PM
americanbankingnews.com logoLeerink Swann Begins Coverage on Arena Pharmaceuticals, Inc. (ARNA)
www.americanbankingnews.com - May 19 at 8:26 AM
finance.yahoo.com logoArena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City
finance.yahoo.com - May 18 at 12:06 PM
prnewswire.com logoArena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial - PR Newswire (press release)
www.prnewswire.com - May 16 at 8:45 PM
finance.yahoo.com logoArena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference
finance.yahoo.com - May 16 at 8:45 PM
americanbankingnews.com logoInsider Buying: Arena Pharmaceuticals, Inc. (ARNA) Insider Buys 25,000 Shares of Stock
www.americanbankingnews.com - May 15 at 11:52 AM
americanbankingnews.com logoArena Pharmaceuticals, Inc. (ARNA) Sees Large Decrease in Short Interest
www.americanbankingnews.com - May 12 at 11:44 PM
nasdaq.com logoArena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down - Nasdaq
www.nasdaq.com - May 10 at 3:48 PM
finance.yahoo.com logoEdited Transcript of ARNA earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 3:48 PM
zacks.com logoArena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down
www.zacks.com - May 10 at 9:12 AM
americanbankingnews.com logoArena Pharmaceuticals, Inc. (ARNA) Posts Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 9 at 9:42 PM
finance.yahoo.com logoArena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:39 PM
marketbeat.com logoArena Pharmaceuticals reports 1Q loss
marketbeat.com - May 9 at 5:21 PM
finance.yahoo.com logoInvestor Network: Arena Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 3:37 PM
americanbankingnews.com logoArena Pharmaceuticals, Inc. (ARNA) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 7 at 7:10 AM
zacks.com logoArena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store?
www.zacks.com - May 5 at 1:46 AM
finance.yahoo.com logoArena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store? - Yahoo Finance
finance.yahoo.com - May 4 at 8:44 PM
nasdaq.com logoArena Pharmaceuticals (ARNA) Q1 Earnings: What's in Store? - Nasdaq
www.nasdaq.com - May 4 at 3:42 PM
finance.yahoo.com logoArena Pharmaceuticals to Release First Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, May 9, 2017
finance.yahoo.com - May 2 at 8:55 AM
americanbankingnews.com logoFavorable News Coverage Extremely Likely to Affect Arena Pharmaceuticals (ARNA) Share Price
www.americanbankingnews.com - May 1 at 12:12 PM
americanbankingnews.com logoArena Pharmaceuticals, Inc. (ARNA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 1 at 12:01 PM
americanbankingnews.com logoAmit Munshi Acquires 50,000 Shares of Arena Pharmaceuticals, Inc. (ARNA) Stock
www.americanbankingnews.com - April 27 at 12:16 PM
americanbankingnews.com logoSomewhat Positive News Coverage Somewhat Likely to Affect Arena Pharmaceuticals (ARNA) Share Price
www.americanbankingnews.com - April 26 at 4:48 PM
prnewswire.com logoArena Pharmaceuticals Announces Completion of Public Offering of ... - PR Newswire (press release)
www.prnewswire.com - April 22 at 3:36 PM
finance.yahoo.com logoArena Pharmaceuticals Announces Completion of Public Offering of ... - Yahoo Finance
finance.yahoo.com - April 21 at 8:43 PM
finance.yahoo.com logoArena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - April 21 at 8:43 PM
247wallst.com logoValeant, Arena Pharmaceuticals in Tuesday's 52-Week Low Club - 24/7 Wall St.
247wallst.com - April 20 at 3:41 PM
finance.yahoo.com logoArena Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ARNA) : April 19, 2017
finance.yahoo.com - April 19 at 3:39 PM
streetinsider.com logoPre-Open Movers 04/18: (IDXG) (GNC) (CAB) Higher; (ARNA) (CAH) (HOG) Lower (more...)
www.streetinsider.com - April 19 at 9:16 AM
zacks.com logoArena Pharma (ARNA) Down After Underwritten Public Offering
www.zacks.com - April 19 at 9:16 AM
finance.yahoo.com logoWhy Is Arena Pharmaceuticals (ARNA) Down 11.3% Since the Last Earnings Report?
finance.yahoo.com - April 19 at 9:16 AM
finance.yahoo.com logoBiotech Industry Outperforming Major Indexes in 2017: Today's Research Reports on Arena Pharmaceuticals and Cytokinetics
finance.yahoo.com - April 19 at 9:16 AM
benzinga.com logoMid-Day Market Update: Dow Drops Over 100 Points; Arena Pharmaceuticals Shares Plummet - Benzinga
www.benzinga.com - April 18 at 3:35 PM
finance.yahoo.com logoWhy Arena Pharmaceuticals Stock Is Getting Hammered Today
finance.yahoo.com - April 18 at 3:35 PM
finance.yahoo.com logoArena Takes a Beating After Lackluster Secondary, Cytokinetics Pops: Biotech Movers
finance.yahoo.com - April 18 at 3:35 PM
feeds.benzinga.com logoMid-Day Market Update: Dow Drops Over 100 Points; Arena Pharmaceuticals Shares Plummet
feeds.benzinga.com - April 18 at 12:25 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Somewhat Likely to Affect Arena Pharmaceuticals (ARNA) Stock Price
www.americanbankingnews.com - April 18 at 11:10 AM
rttnews.com logoArena Pharma Prices Offering Of 60 Mln Shares At $1.15/shr
www.rttnews.com - April 18 at 9:25 AM
streetinsider.com logoArena Pharma (ARNA) Plans Offering of Common Stock
www.streetinsider.com - April 18 at 9:25 AM
finance.yahoo.com logoArena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 18 at 9:25 AM
finance.yahoo.com logoArena Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARNA-US : April 18, 2017
finance.yahoo.com - April 18 at 9:25 AM
finance.yahoo.com logoArena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology
finance.yahoo.com - April 17 at 9:04 AM
americanbankingnews.com logoArena Pharmaceuticals (ARNA) Earns Media Sentiment Score of 0.09
www.americanbankingnews.com - April 13 at 11:42 AM

Social

Chart

Arena Pharmaceuticals (ARNA) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff